Literature DB >> 29806511

Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis.

Rodrigo Athanazio1, Joao Cordeiro da Costa2, David de la Rosa Carrillo3, Miguel Ángel Martínez-García4.   

Abstract

INTRODUCTION: In recent years, there has been an increasing number of clinical trials investigating the effect of pharmacological treatments on patients with bronchiectasis. Areas covered: This review provides an overview of current drugs used in bronchiectasis patients as well as those that could make a future contribution to the management of this disease. Expert commentary: Bronchiectasis is a very heterogeneous disease, so it can be studied from a phenotypic standpoint and its pathophysiological mechanisms (endotypes) can be defined. This provides an interesting field of research as it enables the identification of patients suitable for inclusion in specific clinical trials on new drugs.

Entities:  

Keywords:  Bronchiectasis; bronchial infection; bronchodilators; hypertonic agents; inhaled antibiotics; inhaled steroids; macrolides; mucoactive agents; mucolytics; mucus clearance techniques

Mesh:

Substances:

Year:  2018        PMID: 29806511     DOI: 10.1080/17476348.2018.1481392

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  1 in total

Review 1.  The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies.

Authors:  Kui Li; Li Liu; Yan Ou
Journal:  J Cardiothorac Surg       Date:  2022-10-11       Impact factor: 1.522

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.